Table 3.
Comparison of cardio-cerebrovascular complications and prognosis of PD patients in the two groups during 24 months of follow-up.
| Variable | HR | 95% CI | p |
|---|---|---|---|
| Age (years) | 1.045 | 1.006–1.086 | 0.022 |
| Hb (g/L) | 1.002 | 0.971–1.034 | 0.889 |
| Systolic blood pressure (mmHg) | 1.036 | 1.009–1.065 | 0.009 |
| Diastolic blood pressure (mmHg) | 1.033 | 0.989–1.079 | 0.139 |
| Fasting blood glucose (mmol/L) | 2.532 | 1.593–4.024 | <0.001 |
| rHuEPO use before | 2.620 | 1.068–6.429 | 0.035 |
| Roxadustat treatment | 0.338 | 0.132–0.864 | 0.023 |
| KT/V | 0.619 | 0.233–1.641 | 0.335 |
| Ccr (L/1.73 m2) | 0.987 | 0.972–1.003 | 0.110 |
| Total cholesterol (mmol/L) | 1.151 | 0.775–1.709 | 0.485 |
| LDL-C (mmol/L) | 1.442 | 0.736–2.825 | 0.286 |
| Blood albumin (g/L) | 0.942 | 0.866–1.025 | 0.167 |
| Hypersensitive CRP (mg/L) | 0.950 | 0.834–1.081 | 0.436 |
HR, hazard ratio; CI, confidence interval; Hb, hemoglobin; Kt/V, weekly urea clearance index; Ccr, weekly creatinine clearance; LDL-C, low-density lipoprotein cholesterol; Hypersensitive CRP, hypersensitive C-reactive protein.